聚焦多发性骨髓瘤

虽然免疫抑制剂和蛋白酶体抑制剂的应用使多发性骨髓瘤治疗领域在过去10年取得了显著进展率最低的癌症之一。多发性骨髓瘤目前仍不可治愈，甚至连有效地维持缓解都极为困难。复杂的临床表现、比较研究数据的缺乏导致这一疾病的治疗变得更加复杂。但该疾病仍是预后差且5年存活多样的治疗选择以及长期、大规模受性方面均有显著提高，并且已通过加快审批通道进入市场，用于曾接受过多次既往治疗的患者，治疗复发性／难治性多发性骨髓瘤，但目前还未获得其完整的存活率数据。在基因组学领域，已开始对患者进行更加个体化的预后和治疗，然而这一领域还仅仅处于起步阶段。随着多发性骨髓瘤发生机制的进一步阐明以及竞争前研究合作的进一步加强，希望能够在这一治疗需求远远未被满足的领域快速研发出新—代靶向治疗药物。

Spotlight on Multiple Myeloma

Despite the therapeutic advances made over the last decade with the introduction of the immunornodulatory and proteasome inhibitor drug classes, multiple myeloma is still associated with a poor prognosis and has one of the lowest five-year survival rates in oncology. The disease remains incurable, and successfully maintaining remission is an uphill battle. Therapy is complicated by multiple settings and regimens, with a lack of long-term data from large-scale comparative trials to aid treatment choices. Next-generation drugs with improved etlicacy and tolerability have now entered the market for heavily pre-treated patients following accelerated approval in the relapsed/refractory settings, but the survial data are currently immature. In the genomics era, steps are being taken towards a more personalized approach to prognosis and treatment; however, this field remains very much in its infancy. It is hoped that further elucidation of the molecular mechanisms of multiple myeloma and pre-competitive research collaborations will enable the rapid development of next-generation targeted therapies in this area of high unmet medical need.